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In the past, ABO blood group incompatibility was considered an absolute contraindication for kidney transplantation. Progress
in deﬁned desensitization practice and immunologic understanding has allowed increasingly successful ABO incompatible
transplantation during recent years. This paper focused on the history, disserted outcomes, desensitization modalities
and protocols, posttransplant immunologic surveillance, and antibody-mediated rejection in transplantation with an ABO
incompatible kidney allograft. The mechanism underlying accommodation and antibody-mediated injury was also described.
1.Introduction
The most eﬀective treatment of end-stage renal disease is
kidney transplantation, but a severe donor shortage has sig-
niﬁcantly limited this treatment. To overcome this profound
donor shortage, immunologic barriers historically con-
sidered as absolute contraindications to transplantation are
being reevaluated. One such barrier is the ABO blood
group incompatibility. Kidney transplantation across the
ABO blood group barrier has the potential to expand the
pool of donors, increase the availability of transplantable
organs, and decrease the prolonged time on the waiting list
for a kidney [1–4]. In addition, through the help of a
better understanding of related immunologic mechanisms
and eﬀective various regimens for controlling it, ABO-in-
compatible kidney transplantation (ABOi KT) is being
performed with increasing frequency [5].
Toclarifythecurrentstatusanduncertaintiesinthisarea,
the present paper focuses on recently reported outcomes of
ABOi KT, preconditioning methods before transplantation,
posttransplant monitoring and management, diagnosis and
treatment of antibody-mediated rejection, and the basic elu-
cidation of immune tolerance and accommodation.
2. History of ABO-Incompatible
Kidney Transplantation
2.1. Brief History of ABOi KT. The use of an ABO-incom-
patible (ABOi) kidney is not a recent development. The ﬁrst
attempt at ABOi KT was reported in 1955 by Chung et al.
[6]. In their experience, eight of ten ABOi kidney allografts
did not work successfully within the ﬁrst few postoperative
days. Although further attempts at ABOi KT have been spo-
radically reported, these series revealed similar poor out-
comes with graft survival rates of approximately 4% at one
year [7–10]. Therefore, ABOi KT was largely abandoned.
An interesting clinical trial was reported in 1987 when
Thielke et al. [11] showed that 12 of 20 transplants from
blood group A2 donors into O recipients maintained long-
term allograft function. This procedure is based on the
ﬁnding that the expression of the A antigen on the red blood
cell in the A2 donor was much weaker than that in the A1
donor. Regrettably, this technique can be used only in a small
minority of KT candidates.
In 1987, Alexandre et al. introduced an eﬀective desensi-
tization protocol to achieve success in ABOi living donor KT2 Journal of Transplantation
[11]. This protocol included pretransplant repeated plasma-
pheresis as a strategy not only to reduce the titers of anti-
A or -B antibodies, but also to decrease the antilymphocyte
globulin-based induction. This plasmapheresis also altered
the triple maintenance immunosuppression of cyclosporine,
azathioprine, and corticosteroids and concomitant splenec-
tomy [12]. A one-year graft survival of 75% and a recipient
survival of 88% were achieved in the 23 recipients [2]. While
their results were impressive and became the basis of the next
desensitization protocols for ABOi KT, the ABOi KT was still
uncommon in the west.
These eﬀorts regarding ABOi KT were signiﬁcantly ex-
panded in Japan because of the near absence of deceased
donors and the only 0.15% of living A2 donors. The largest
number of ABOi KT since 1989, more than 1000 cases, has
been performed in Japan [13]. The percentage of ABOi KT
surgeries reached 14% of all living donor KTs performed in
Japan [11]. Following the remarkable results reported in the
Japanese center utilizing modern desensitization techniques,
together with the development of new immunosuppressive
therapies, ABOi KT began receiving new interest in Europe
and the USA in the early 2000s [12].
2.2. Published Clinical Outcomes of ABOi KT. Short-term
results from the protocol described above have been notable.
For instance, in the study of Tyd´ en et al. [14], recipients
with a baseline anti-A or -B IgG titer of up to 1:128 were
successfully transplanted with no episode of acute rejection.
Montgomery [15] reported one-year patient and graft sur-
vivals of 96.3% and 98.3%, respectively, in a cohort of 60
consecutive ABOi KTs using a variety of protocols. Oettl et
al. [16] demonstrated a 100% survival rate of both patients
and grafts at one-year after transplant.
Moreover, long-term results of ABOi KT reported by
westernandJapanesetransplantcentersalsohaveshownthat
ABOiKTisequivalenttoABO-compatibleKT[12].Genberg
et al. [17] reported that ABOi KT had no negative impact
on long-term graft function compared to that of ABO-com-
patible KT in terms of patient survival, graft survival, or
incidence of acute rejection after a mean followup of three
years. Tyd´ en et al. [18] found that graft survival was
97% for the ABOi KT compared with 95% for the ABO-
compatible KT in their three-center experience at their ﬁve-
yearfollowup.Patientsurvivalswere98%inbothKTgroups.
In the analyzed UNOS data of Gloor and Stegall [19],
they concluded that a long-term immunological response
against ABO incompatibility has little eﬀect on graft survival
with current immunosuppressive protocols and patient
monitoring. Tanabe [20] summarized the outcomes of 851
ABOiKTperformedin82institutionsinJapanbetween1989
and 2005. The ﬁve-year graft survival in their study was 79%,
with patient survival at 90%. Montgomery [15] obtained
ﬁve-year patient and graft survivals of 89% following ABOi
KT at Johns Hopkins Hospital. Fuchinoue et al. [21]r e p o r t
the ﬁve-year outcome of ABOi KT as a graft survival rate of
100%, whereas Ishida et al. [13]a c h i e v e dag r a f ts u r v i v a lo f
57% and patient survival of 89% at ten years postoperatively
for more than 130 cases of ABOi KT.
3. CurrentStatus of ABO-Incompatible
Kidney Transplantation
3.1. General Methodology of Desensitization. For the success-
ful performance of ABOi KT, the antibody-mediated re-
sponse must be understood and targeted. Over the past 20
years, several strategies have been developed to resolve and
modulate this response. These strategies, or desensitizations,
are all based on the same principles [5, 12, 22], including not
only the removal of preexisting antibodies that are directed
at the donor ABO antigen, but also waiting to transplant
until the anti-ABO antibody titer is below a set target.
Additionally, the prevention of further production of new
recipient anti-ABO antibodies before and after transplanta-
tion is another founding principle.
Ordinarily, several pretransplant apheresis sessions are
required for antibody removal. To prevent reformation of
the antibody, apheresis is followed by intravenous immuno-
globulin, a mixture of immunosuppressive therapies, and
erasable splenectomy [11, 12]. This procedure usually occurs
over a period of one to two weeks.
3.2. Speciﬁc Preconditioning Modality
3.2.1. Antibody Depletion Technique. In the ﬁeld of ABOi KT,
currently used antibody depletion techniques include ther-
apeutic plasma exchange, double-ﬁltration plasmapheresis,
and antigen-speciﬁc immunoadsorption. The great diﬀer-
ence among these techniques is their degree of selectivity
[12].
The simplest and most common method to remove an-
tibody from plasma is therapeutic plasma exchange, in
which large amounts of plasma are withdrawn and replaced
with colloid solutions [23]. This procedure eliminates ap-
proximately 20% of the anti-ABO antibodies with each
session. However, this technique is not suﬃciently selective
to remove only protective antibodies and also removes coag-
ulation factors, hormones, and antiviral and antibacterial
immunoglobulin G (IgG) and immunoglobulin M (IgM).
The removal of these factors increases the risk of bleeding
or infection [24]. However, this technique is by far the least
expensive means of removing antibodies [12].
Theselectivetechniquesofdouble-ﬁltrationplasmapher-
esisorantigen-speciﬁcimmunoadsorptionaresafeandmore
eﬀective and are therefore usually the ﬁrst choice. Because
no coagulation factors are eliminated, large plasma volumes
can be processed, and the resultant eﬃcacy is increased com-
pared to that of therapeutic plasma exchange [12]. Using a
second ﬁlter, double-ﬁltration plasmapheresis is capable of
eliminatingtheplasmafractioncontainingtheimmunoglob-
ulins [12] and decreases the amount of plasma discarded
[23]. Using the process of immunoadsorption, the plasma
is processed through a Glycosorb ABO immunoadsorbent
column and reinfused into the patient. There are no volume
losses, and thus the number of adsorption cycles has no limit
[23]. Although the ABOi KT is an American Society for
Apheresis (ASFA) category II indication, there has been no
clinicaltrialdiﬀerentiatingantibodyreductionproceduresor
the standardized monitoring protocol [4].Journal of Transplantation 3
3.2.2. Intravenous Immunoglobulin. Intravenous immuno-
globulin plays a role in the downregulation of the antibody-
mediated immune response [5]. The immunoglobulin
blocks not only the Fc receptor on the mononuclear phago-
cyte, but also the direct neutralization of the alloantibody.
Further, it inhibits the CD19 expression on the activated B
cell, as well as that of the complement and the alloreactive
T cell. Although alloantibody rebounds within days of the
discontinuationofplasmapheresis,thebeneﬁtofintravenous
immunoglobulin may continue for many months after drug
administration.
3.2.3. Splenectomy. Traditionally, concurrent splenectomy
was an important prerequisite of the desensitization protocol
for ABOi KT, based on the idea that it contributed to
the reduction of the antibody-producing B-cell pool [5].
Alexandre et al., the early investigator of ABOi KT, suggested
that the splenectomized recipient had a much smaller risk of
antibody-mediated rejection.
However, whether splenectomy is essential for successful
ABOi KT remains unproven. Sonnenday et al. [2] found that
the suppression of anti-ABO antibody after splenectomy was
not signiﬁcantly diﬀerent from that of nonsplenectomized
patients. Sonnenday et al. [2] reported that splenectomized
recipients had a 25% greater mortality at 84 months
compared with that of non-splenectomized recipients. Gloor
et al. [25] reported that splenectomy is not necessary even
for patients with high-baseline anti-ABO antibody titers.
Takahashi et al. [26] demonstrated that splenectomy is not
necessary to inhibit antibody production because signiﬁcant
numbers of memory cells exist in the bone marrow.
There is a growing consensus that splenectomy is not
necessary in ABOi KT recipients [19]. Most investigations
havecommonlysubstitutedanti-CD20monoclonalantibody
induction [5].
3.2.4. Anti-CD20 Monoclonal Antibody. The anti-CD20
monoclonal antibody, rituximab, directly inhibits B-cell pro-
liferation and induces cellular apoptosis through the binding
of complement. Complement, in turn, mediates antibody-
dependent cell-mediated cytotoxicity and subsequent cell
death [27].
Several centers have established the use of rituximab as
a chemical splenectomy due to its potent ablation of the
B-cell compartment [20]. The advantage of rituximab over
splenectomy is that it ablates the B cell during the period
of the greatest risk of antibody-mediated rejection and then
allows the humoral immune system to heal with an intact
spleen [28]. Fuchinoue et al. [21] reported that patients who
received rituximab induction had a lower incidence of acute
antibody-mediated rejection and better outcome of ﬁve-
year graft survival compared to those in ABO-compatible
or -incompatible KT recipients who were not treated with
rituximab.
However, rituximab’s mechanism of action in ABOi KT
is not clear. Since CD20 antigen is not expressed on plasma
cells, rituximab is eﬀective against pre-B and B-cells but
not against plasma cells, which contributes to antibody
production [26]. Some data [24] suggest that rituximab has
a much weaker impact on the memory B cell population, the
progenitor of the IgG-secreting plasma cell. The appropriate
dosage and the initial time for administration were also
unclear. Toki et al. [29] indicated that a low-dose rituximab
less than 375mg/m2 has a potent impact on the depletion
of B cells in the spleen and peripheral blood. Toki et al.
[29] demonstrated that a single dose of rituximab, even at
50mg/m2, depleted B cells from the peripheral blood as
eﬀectively as did the 375mg/m2 dose. Fuchinoue et al. [21]
revealed that there was no diﬀerence in serum creatinine
at one year after transplant, irrespective of the dose of
rituximab.
As an extension of this idea, these have led to a modiﬁed
protocol that consists of an antibody-depleting procedure
and intravenous immunoglobulin with no long-term B-cell
suppression from splenectomy or rituximab. Flint et al. [30]
and Montgomery et al. [31] have applied this protocol to
their cohort studies. Montgomery’s results showed that the
ﬁve-year graft survival rate was 88.7% with no instance of
antibody-mediated rejection or graft loss.
3.2.5. Quadruple Immunosuppression. Immunosuppressive
regimens are required for both T-cell-mediated immu-
nity and B-cell-mediated immunity, which are similar
to that used for ABO-compatible KT [26]. Calcineurin
inhibitors (cyclosporine and tacrolimus) and antimetabo-
lites (mycophenolate mofetil and azathioprine) are mainly
used with low-dose steroids. In addition, monoclonal or
polyclonal antibody agents (anti-CD25 antibody or antithy-
mocyte globulin) are also often used during the induction
period.Tanabe[20]startedtousetacrolimusincombination
with mycophenolate mofetil as a basic immunosuppressant
afterABOiKTand reported agreatlyimproved graftsurvival
compared with that of cyclosporine administration.
Antimetabolites seem to take seven∼ten days to be eﬃ-
cient as in vivo immunosuppressants. Therefore, immuno-
suppressive therapy as desensitization should be started
before transplantation in order to adequately inhibit anti-
body production [20].
3.3. Current Desensitization Protocols. In order to achieve a
successful outcome with ABOi KT, many centers have em-
ployed their own independent desensitization protocols.
Although there are slight diﬀerences in the precondi-
tioning formalities depending on the transplant center,
most include a combination of pretransplant plasmaphere-
sis, intravenous immunoglobulin, and tacrolimus-myco-
phenolate-based immunosuppression with antibody induc-
tion. Splenectomy or rituximab administration is used selec-
tively. After transplant, very close monitoring of the anti-
ABO antibody titer is typically carried out for a minimum of
two weeks. If necessary, plasmapheresis is added to eliminate
the rebounding antibody level [5, 15]. The details are shown
in Table 1.4 Journal of Transplantation
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4. UncertaintiesinABO-Incompatible
Kidney Transplantation
4.1. Graft Accommodation and B-Cell Tolerance. If anti-ABO
antibodies are removed prior to transplantation, one of three
types of immune response may occur: rejection, immune
tolerance, or accommodation [32]. (1) About 2–5% of
patients produce antibodies to the incompatible ABO anti-
gen, which mediate allograft rejection. (2) Some recipients
seem to have immunologic tolerance to the incompatible
ABO antigen because they do not reject the allograft or
produce anti-ABO antibody against it. (3) The others display
an accommodation state regarding the allograft [33].
Theoretically, natural anti-ABO antibody might be in-
ducing antibody-mediated rejection in ABOi KT [26]a n d
can manifest as a hyperacute rejection or as an acute or
delayed humoral rejection. Antibody-mediated damage can
result in rapid and irreversible graft thrombosis due to
complement activation or contributes to long-term graft
dysfunction[34].However,astheanti-ABOantibodyusually
reaccumulates and persists after successful ABOi KT, the
recipient maintains satisfactory graft function. This resis-
tance of allograft to antibody-mediated rejection despite the
signiﬁcant presence of anti-ABO antibodies in the recipient
serum is known as accommodation [1, 5, 35, 36].
Park et al. [1] deﬁned the criteria of accommodation in
ABOi KT to include (1) detectable anti-ABO antibody in
the recipient serum, (2) normal graft histology according
to light microscopy, (3) the presence of A or B antigen in
the graft, and (4) renal function similar to that of ABO
compatible patients (GFR greater than 45mL/min at one-
year after transplant). In 2006, the American Society of
Transplantation reached a consensus on accommodation,
stating that it occurred when C4d deposition was detected
with normal function and structure of the graft [35].
How accommodation is induced and through what
mechanism it is maintained are not well understood. Various
hypotheses have been proposed to describe the mechanism
responsible for accommodation [34, 37], including changes
in the function of antidonor antibody, changes in the an-
tigen, acquired resistance of the allograft through the ex-
pression of an antiapoptotic gene, or an expression of com-
plement regulatory protein.
The study of Ishida et al. [33] presented the diﬀerence
in quality between antibodies produced by accommodated
and non-accommodated recipients. Kirk et al.[38]s u gg e s t ed
that accommodation is related to a shift from the IgG
isotype to the IgG2 isotype that is less eﬀective at activating
complement and that competitively inhibits the binding of
the more cytotoxic isotype. Chang and Platt [39] discovered
that healthy organs could absorb antidonor antibody in large
amounts, for which the accommodated functioning graft
served as a sink. According to these results, accommodation
may reﬂect a change in the properties of the antibody or
antigen.
Park et al. [1] and Delikouras and Dorling [40]r e p o r t e d
that the Bcl-2 and Bcl-xl, antiapoptotic molecules, were
foundintheaccommodatedABOincompatiblekidneygraft.
However, Bax, a proapoptotic marker, was not detected.
Salama et al. [41]d e m o n s t r a t e du p r e g u l a t i o no fB c l - x Li n
the microvascular endothelial cells of accommodated grafts.
These ﬁndings are consistent with the hypothesis that the
endothelium of the kidney allograft will be initially exposed
to low titers of anti-ABO antibody, which will in turn in-
stigate a series of protective changes that manifest as accom-
modation.
Consistent with this concept, data from Stegall et al.
[42] suggest that a decrease in tumor necrosis factor-α
and alteration in SMAD (mothers against decapentaplegic
homolog) gene expression may be important in long-term
accommodated grafts. Griesemer et al. [35] introduced the
concept that the upregulation of a complement regulatory
protein such as CD59 seems to be involved in accommoda-
tion by preventing the formation of the membrane attack
complex (MAC) on the accommodated graft.
Accommodation is diﬀerent from immune tolerance.
The accommodated allograft kidney remains protected even
though it is transplanted into a new recipient. However, an
immunotolerant allograft preserves the potential to reject
the tissue from the same donor. Immune tolerance is a
state of immune unresponsiveness to the presence of speciﬁc
non-self-antigens in the absence of long-term immunosup-
pression. Published studies have provided evidence that B
cells have an important role in tolerance. Kirk et al. [38]
postulatedthattheprolongeddepletionofalloreactiveBcells
in tolerant mice is achieved through the dominant and active
suppression of T helper cells. Ogawa et al. [32]s u g g e s t e d
that prolonged T-cell suppression in the ABOi KT recipient
may result in a similar induction of tolerance to that of the
incompatible ABO antigen.
4.2.PosttransplantMonitoringandDesensitization(Posttrans-
plant Immunologic Surveillance). The monitoring of anti-
ABO antibody titer is critical for determining the eﬀective-
ness of desensitization and the optimum time to permit graft
implantation. After transplantation, the anti-ABO antibody
level must be monitored to detect its reaccumulation, which
may indicate or induce antibody-mediated rejection. In
patients with a higher rebound in serum antibody pro-
duction after the incompatible transplant, desensitization
therapy, especially antibody-depletion procedures, should be
repeated. Most studies [3, 43] agree that posttransplant
DFPP was ineﬀective at preventing the rebound of anti-
ABO antibody titers compared to the eﬃcacy of therapeutic
plasma exchange.
The Jones Hopkins group of Montgomery et al. [15, 28]
determined the initiation of posttransplant plasmapheresis
based on the pretransplant baseline antibody level before
preconditioning. Others [44] have granted that preemptive
posttransplant plasmapheresis may be dispensable, favoring
an on-demand strategy according to the post-transplant
antibody titer elevation. However, there are conﬂicting
opinionsonwhichantibodytiterismeaningfulandhowlong
antibody monitoring should continue.
Kayler et al. [45] found that all patients whose posttrans-
plant antibody titer remained below 1:8 exhibited stable
renal function. Those patients who had an increased titerJournal of Transplantation 7
above 1:64 experienced allograft failure. Stegall et al. [42]
recommended initiating plasmapheresis if the antibody titer
increases to 1:16 in the ﬁrst two weeks after transplantation.
Gloor et al. [25] showed that humoral rejection was rare
when the antibody level was maintained less than 1:8 in the
ﬁrst week and 1:16 in the second week after transplantation.
They then allowed antibody titers to rise if the graft function
and surveillance biopsies were normal. Takahashi [46, 47]
asserted that anti-ABO antibody titers should be suppressed
tothelowestlevelduringtheﬁrstweekaftertransplant,when
surface antigenicity is increasing in the vascular endothelial
cells of the graft kidney.
On the other hand, Park et al. [1] demonstrated that
anti-ABO antibody titers return to detectable levels in all
accommodated and nonaccommodated recipients, even in
the absence of humoral rejection or chronic graft damage.
Tobian et al. [3] also demonstrated that the clinical signiﬁ-
canceofanincreasedposttransplantanti-ABOantibodylevel
is variable, and that there was no dependable correlation for
antibody-mediated rejection. These ﬁndings are supported
by the fact that a high titer of antibody is generally necessary
but is not suﬃcient for antibody-mediated rejection.
4.3. Acceptable Anti-Blood Group Titer at the Time of Trans-
plant. Before the initiation of preconditioning, the baseline
anti-ABO antibody titer is well known as a signiﬁcant
predictor of the severity of antibody-mediated graft injury as
well as graft survival [19, 42]. Although a few recent reports
have shown that a high-baseline antibody titer is no longer
predictive for poor graft outcome in patients that received
tacrolimus- or mycophenolate mofetil-based immunosup-
pression [6, 19] ,a n t i b o d yr e m o v a ls h o u l db ea sc o m p l e t ea s
possible.
Most centers performing ABOi KT have adhered to
the guideline that serum anti-ABO antibody titers should
be 1:16 or lower before transplantation [26]. However,
the acceptable upper limit of anti-ABO antibody titers is
exclusively based on empirical evidence, not substantiated
by deductive reasoning. Wilpert et al. [48] decreased the
antibodytitertobelow1:4beforetransplant,whileChunget
al.[6]chosealimitof1:32intheirpreconditioningprotocol.
Some institutions use the antiglobulin IgG antibody titer
endpoint as the critical titer when assessing patients before
and after transplantation. Others consider both IgM and IgG
antibody titers [4]. Which type of anti-ABO antibody, IgM
or IgG, causes antibody-mediated graft damage due to the
unique characteristics of the antibody remains unclear [49].
If anti-ABO IgG antibodies are believed to be responsible
for worse graft outcomes, it is expected that blood group O
recipients will be more likely to suﬀer graft damage than will
A or B recipients.
4.4. Antibody-Mediated Rejection. Antibody-mediated rejec-
tion (ABMR) is known as the primary cause of graft loss
in ABOi KT. It is clear that ABMR has a negative inﬂuence
on short-term outcome following ABOi KT. Recent studies
have reported that ABMR occurred in 17.9% up to 30% of
ABO-incompatiblekidneytransplants[22,50,51].Tokietal.
[50]demonstratedthatanti-ABOIgGantibodytitersof1:32
at the time of transplantation and the presence of donor-
speciﬁc anti-HLA antibodies were independent risk factors
for ABMR. Although the development of desensitization
protocols has improved graft survival [50], the outstanding
results are largely due to aggressive surveillance, early de-
tection, and an enhanced therapeutic approach for ABMR
[45].
The hyperacute rejection due to anti-ABO antibody does
not occur within 24 hours, which is called the silent period.
The greatest incidence of acute antibody-mediated rejection
occurs two to seven days after transplant and does not typ-
ically occur after more than one month. Some researchers,
therefore, have deﬁned the ﬁrst two weeks after transplan-
tation as the critical period during which accommodation
is usually induced and established. Once accommodation
is established, acute antibody-mediated rejection does not
occur, leading to the stable period [26].
Takahashi [26] classiﬁed acute ABMR into two types on
the basis of antigen stimulation. Type I ABMR is caused
by resensitization due to recovery of the ABO antigen.
ABO antigen in the graft directly stimulates immunological
responses, resulting in an explosive antibody production
early in the critical period, typically, IgG antibody. Type II
ABMR is caused by primary sensitization due to an ABO
blood-group-associated antigen. In response to bacterial
infection, an ABO-antigen-like substance is found on the
surfaces of bacterial cells, acting as a cross-reacting antigen
to cause sensitization and antibody production, mainly IgM.
This type II rejection usually progresses more slowly and is
less severe than is type I rejection.
4.5. Diagnosis of Acute Antibody-Mediated Rejection. Clini-
cally, ABMR was suspected when the serum creatinine level
was increased relative to the previous value, together with a
decrease in urine output. Renal biopsy is typically performed
in such suspected cases [21]. Acute ABMR after ABOi KT is
diagnosed on the basis of morphologic, immunohistologic,
and serologic features. Morphologic evidence includes (1)
leukocyte (neutrophil, monocyte, and macrophage) inﬁl-
tration into the peritubular capillary and/or glomeruli;
(2) arterial ﬁbrinoid necrosis; (3) glomerular and arte-
rial thrombi; (4) acute tubular injury. Immunohistologic
evidence involves (1) peritubular capillary C4d deposition
and (2) immunoglobulin and/or complement in arterial
ﬁbrinoid necrosis. For serologic evidence, circulating speciﬁc
antidonor antibodies at the time of biopsy should be found.
Overall, at least one ﬁnding in each of the three categories
must be present for a biopsy to be diagnosed as acute ABMR
[22, 25, 52]. These diagnostic criteria were established by the
National Institutes of Health and the Banﬀ working group.
The former group also requires clinical evidence of graft
dysfunction, while the latter group accepts the possibility
of subclinical acute ABMR, deﬁned as C4d staining and
leukocyte margination in the peritubular capillary in a
protocol biopsy of a well-functioning graft [52].
Antibody-mediated rejection is thought to be caused
by endothelial cell activation in the graft [39]. Peritubular8 Journal of Transplantation
capillary C4d deposition has been considered to be an
important histologic indicator of antibody-endothelial cell
interaction and is a key element in the diagnosis of ABMR.
The presence of donor-speciﬁc antibody or the presence of
C4d alone in the peritubular capillary is not diagnostic of
acute ABMR in the setting of ABOi KT [5, 19]. Racusen
and Haas [52] reported that C4d staining was associated
with ABMR and graft injury in the malfunctioning graft,
whereas it reﬂected graft accommodation in the stably
functioning graft. Setoguchi et al. [53] detected C4d staining
in the peritubular capillary in 94% of their protocol biopsy
specimens but in only 28% of subclinical ABMR cases.
Haas et al. [54, 55] observed C4d deposition in 80% of
protocol biopsies in the absence of allograft dysfunction or
other histologic abnormalities suggestive of acute ABMR.
Meanwhile,they[54]suggestedthatdepositionofC3d,alone
orincombinationwithC4d,mayidentifyamoresevereform
of ABMR associated with a high risk of graft loss.
4.6. Treatment Strategy for Acute Antibody-Mediated Rejec-
tion. Basically, ABMR was treated through the reinitiation
of plasmapheresis to remove circulating antibodies [19,
53]. Plasma exchange for the treatment of rejection was
ﬁrst reported in 1977 [43]. Just et al. [56]r e p o r t e da n
immunoadsorption-based protocol to eliminate deposited
IgG from the allograft.
Standard treatment for ABMR consists of repeated
plasmapheresis-plasma exchange or immunoadsorption and
intravenous immunoglobulin [57]. Various combinations of
these therapeutic modalities have been successfully used to
treat ABMR and improve outcomes. Most institutes [25, 58,
59]treatedABMRwithaseriesofplasmaexchangesfollowed
by low-dose IVIG in addition to methylprednisolone until
clinical improvement was achieved or until ABMR was his-
tologically determined to have been resolved. Racusen and
Haas [52] reported that reversal rates for ABMR were
approximately 90% using such protocols, contrasted to
reversal rates of less than 50% with traditional immuno-
suppression alone. Rituximab, an immunosuppressive agent
which controls antidonor antibody production, and several
complement inhibitors have also been reported to obtain
signiﬁcant eﬃcacy [60].
The use of rituximab is intended to deplete B cells and
thereby suppress antibody production. Several doses of rit-
uximab at 375mg/m2 were intravenously administered to
resolve ABMR [27]. Garrett et al. administrated rituximab
as a ﬁrst-line therapy for ABMR. Sarwal et al. noted that
allografts with CD20+ cells in biopsy specimen were strongly
associated with the clinical phenotype of glucocorticoid
resistance and chose to treat ABMR with rituximab.
Together with tacrolimus-mycophenolate rescue, the
majority of AMBR cases have received antithymocyte glob-
ulin at the time of plasmapheresis [57]. Toki et al. [50]
administered OKT3 at a dose of 5mg/day for seven days in
patients with persistent antibody-mediated rejection.
Previously mentioned anti-ABMR therapies including
plasmapheresis, intravenous immunoglobulin, antithymo-
cyte globulin, and rituximab have provided suboptimal
results [61]. One reason for this insuﬃcient success is that
they do not exert direct eﬀects on the mature plasma cell.
A proteasome inhibitor, such as bortezomib, depletes both
transformed and nontransformed plasma cells in animal and
human transplant recipients. Recent reports have also shown
that eculizumab, a humanized monoclonal antibody against
terminal complement protein C5, is an eﬀective therapy
to inhibit terminal complement activation and prevent
antibody-induced injury. All of these modes are useful in the
treatment of refractory ABMR [24, 57].
Splenectomy may be a possible option as a rescue
treatment for severe ABMR resistance to standard treatment
after ABOi KT. Kaplan et al. [60] reported the ﬁrst early
experience with rescue splenectomy and suggested that the
procedure may speciﬁcally and irreversibly deplete memory
B cells, thus oﬀering an additive eﬀect to the standard
treatment.
4.7.ChronicAntibody-MediatedRejection. Althoughsuccess-
ful strategies have been developed to treat acute ABMR,
humoral alloreactivity in the early posttransplant period
adversely impacts long-term allograft survival and con-
tributes to chronic rejection [54]. Toki et al. [50] revealed
that a high panel-reactive antibody value was signiﬁcantly
associated with the development of chronic ABMR char-
acterized by transplant glomerulopathy. Recent studies [19,
50] have found that a prior history of ABMR was sig-
niﬁcantly associated with the development of transplant
glomerulopathy, with an incidence of 22% at one year after
transplantation. Smith et al. [37] clariﬁed sequential stages
of chronic ABMR using an animal model and determined
thattheﬁrstsymptomwascirculatingalloantibody,C4d,ora
combination of the two.Only rarelywastransplant glomeru-
lopathy observed in the absence of C4d or alloantibody.
The National Institutes of Health suggested diagnostic
criteria for chronic ABMR in ABOi kidney allograft [52].
Their criteria require three of the following four lesions: (1)
arterial intimal ﬁbrosis, (2) interstitial ﬁbrosis/tubular atro-
phy, (3) duplication of the glomerular basement membrane,
or (4) lamination of the peritubular capillary basement
membranes.
4.8. Minimizing Immunosuppressive Therapy. ABOi KT is
consideredanincreasedimmunologicrisk;therefore,aggres-
sive immunosuppressive protocols traditionally have been
used[11].Mostcentershaveadoptedpolyclonalantibodyfor
the induction and chronic maintenance of immunosuppres-
sion based on tacrolimus and mycophenolate, starting two
weeks before the transplantation.
Nevertheless, Chuang et al. [62] showed that main-
tenance-immunosuppressive therapy did not aﬀect isoagglu-
tinin titer in ABOi KT. In addition, no signiﬁcant diﬀerence
in isoagglutinin titer was observed between tacrolimus and
cyclosporine groups. Flint et al. [30] demonstrated that only
standard immunosuppression could produce a successful
ABOi KT as long as an adequate desensitization protocol
wasemployed.Farfromhighimmunologicrisk,avoidanceof
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KT recipients. Magee [5] avoided lymphocyte-depleting
antibody because it is no more eﬀective in preventing
ABMR and is adversely associated with a higher incidence of
infective complications.
The long-term need for steroids remains a question in
ABOi KT. Crew and Ratner [24] and Galliford et al. [58]
reported that ABOi KT can be successfully accomplished
using a steroid-sparing regimen without resulting steroid-
resistant rejection.
5. Conclusions
The idea that ABO blood group incompatibility should be
consideredanabsolutecontraindicationtokidneytransplan-
tation has been challenged in the past two decades. As the
pretransplant and posttransplant desensitization protocols
have developed and changed in many diﬀerent ﬁelds, sat-
isfactoryresultshavebeenobserved.Asthebodyofimmuno-
logic knowledge including that regarding antibody-mediated
rejection has grown, the allograft outcomes have been
enhanced. Overall success rates are now comparable with
those of ABO-compatible kidney transplantation. Due to the
surprising result, the pool of potential ABOi KT candidates
has increased.
Because the long-term outcome of ABOi KT has not yet
been determined, uncertain and contentious ideas regarding
it use still exist. Despite this, ABOi KT has become one of the
established therapies. These inspiring circumstances fore-
cast a hopeful future for ABO-incompatible kidney trans-
plantation.
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